US tax reform: Implications for pharma and life sciences

In December 2017, the United States enacted the most comprehensive tax reform in more than 30 years. For the pharmaceutical and life sciences sector, the changes will impact both US and non-US headquartered companies doing business in the United States.

Topics

Continue reading with a PwC Plus-Subscription

  • verified Information source
  • daily updates
  • completely searchable articles (with refiner)
  • tailored alert
To the top